Omega Healthcare Q2 net income, adjusted FFO rise; lifts 2026 outlook
OHI•Analyst coverage
The current average analyst rating on the shares is hold, with 7 strong buy or buy ratings, 10 hold ratings and 2 sell or strong sell ratings.
The average consensus recommendation for the specialized REITs peer group is buy.
Wall Street's median 12-month price target for Omega Healthcare Investors, Inc. is $51.00, about 1.2% below its July 28 closing price of $51.64. The stock recently traded at 26 times the next 12-month earnings versus a P/E of 22 three months ago.
Key financial metrics
| Metric | Actual |
|---|---|
| Q2 EPS | $1.19 |
| Q2 Net income | $380 million |
| Q2 Adjusted FFO | $261 million |
Drivers of the quarter
- New investments — $126 million in second-quarter investments, including $110 million in real estate acquisitions and $16 million in loan fundings, contributed to growth.
